PYC Therapeutics (ASX:PYC) has announced that the Safety Review Committee governing the Phase 1 clinical trial of VP-001 being studied in Retinitis Pigmentosa type 11 has approved the escalation of dosing to patient cohort 3. …
PYC Therapeutics progressing to high dose patient cohort in RP11 trial
December 18, 2023 Australian Biotech
Latest Video
New Stories
-
Todd Stephenson confirmed on ACT list for New Zealand election
September 14, 2026 - - Latest News -
Scandal-hit KPMG still holds $37 million in health department work
September 14, 2026 - - Latest News -
Canberra details tax changes with limited concessions for some innovators
September 14, 2026 - - Latest News -
The 'Dispatched' Week in Review Podcast - 11 September
September 11, 2026 - - Podcast -
Rare genetic motor neurone disease treatment finally reaches Australian patients
September 11, 2026 - - Latest News -
NSW pharmacists to deliver all childhood vaccines and treat more conditions under reforms
September 11, 2026 - - Latest News -
AI Health Summit 2026
September 10, 2026 - - Summit